Orbimed Advisors
Mar 12, 2020
JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19
The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC) The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
